衰弱、PaO2/FiO2比值与院内死亡率之间的关联:一项基于注册数据库的回顾性队列研究
该回顾性多中心注册队列研究纳入澳大利亚新西兰重症监护学会成人患者数据库中191个ICU的497,185例成人患者,按PaO2/FiO2分为无AHRF(≥300)、轻度(200-300)、中度(100-200)、重度(<100),以CFS≥5定义衰弱。衰弱患者97,317例(19.6%),AHRF在衰弱者中更常见(58.3% vs 49.0%)。总院内死亡率7.4%(36,791/497,185),衰弱者更高(16.4% vs 5.2%)。衰弱合并AHRF者死亡率随AHRF加重而升高,且各CFS类别内CFS评分越高死亡率绝对差异越大;校正混杂后衰弱、PaO2/FiO2与院内死亡率呈非线性关系,各CFS类别间清晰分离。
要点
- 衰弱(CFS≥5)患者占19.6%(97,317/497,185),其AHRF发生率高于非衰弱者(58.3% vs 49.0%)。
- 总院内死亡率7.4%(36,791/497,185),衰弱者16.4% vs 非衰弱者5.2%。
- 衰弱合并AHRF者院内死亡率随AHRF严重度增加而升高,绝对差异随严重度增大。
- 各CFS类别内,CFS评分越高,死亡率绝对差异越大。
- 校正混杂后,衰弱、PaO2/FiO2与院内死亡率呈非线性关系,各CFS类别间清晰分离。
适用人群与场景
- 所有成人(≥16岁)患者,2017年1月1日至2023年3月31日入住191个ICU,且在最初24小时内行动脉血气分析。
- 按PaO2/FiO2分类:无AHRF(≥300)、轻度AHRF(200-300)、中度AHRF(100-200)、重度AHRF(<100)。
- 衰弱定义为临床衰弱量表(CFS)≥5。
诊断标准与关键阈值
- 急性低氧性呼吸衰竭(AHRF)分类依据PaO2/FiO2:无AHRF ≥300,轻度200-300,中度100-200,重度<100。
- 衰弱定义:临床衰弱量表(CFS)≥5。
研究设计与关键结果
- 研究类型:回顾性多中心注册数据库观察性研究,使用澳大利亚新西兰重症监护学会成人患者数据库;样本量497,185例,191个ICU。
- 衰弱患者97,317例(19.6%);AHRF在衰弱者中更常见(58.3% vs 49.0%)。
- 总院内死亡率7.4%(36,791/497,185);衰弱者死亡率16.4% vs 非衰弱者5.2%。
- 衰弱合并AHRF者院内死亡率随AHRF严重度增加而升高,绝对差异随AHRF严重度增大。
- 各CFS类别内,CFS评分越高,死亡率绝对差异越大。
- 校正混杂因素后,衰弱、PaO2/FiO2与院内死亡率呈非线性关系(限制性立方样条,四个节点),各CFS类别间清晰分离。
- 预设亚组分析基于年龄(<65岁 vs ≥65岁)、机械通气状态和ICU出科存活患者。
证据类型、等级与局限
- 证据类型:回顾性多中心注册数据库观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:AHRF在衰弱患者中高度流行;衰弱增加与AHRF患者院内死亡率升高相关,且随AHRF严重度增加而升高,呈非线性关系。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: While research into critically ill patients with acute hypoxemic respiratory failure (AHRF) is growing, how this interacts with frailty is currently unknown.
DESIGN: A retrospective multicentric registry-based observational study using the Australia New Zealand Intensive Care Society Adult Patient Database.
SETTING AND PATIENTS: All adult (≥ 16 yr) patients admitted to 191 ICUs from January 1, 2017, to March 31, 2023, with an arterial blood gas sample within the first 24 hours were included. We categorized patients as having no AHRF (Pa o2 /F io2 ≥ 300), mild AHRF (Pa o2 /F io2 200-300), moderate AHRF (Pa o2 /F io2 100-200), and severe AHRF (Pa o2 /F io2 < 100). We defined frailty as a Clinical Frailty Scale (CFS) greater than or equal to 5.
INTERVENTIONS: None.
MAIN OUTCOMES: The primary outcome was in-hospital mortality.
MEASUREMENTS AND MAIN RESULTS: We evaluated the association between Pa o2 /F io2 ratio and risk-adjusted mortality using restricted cubic splines with four knots. We conducted predefined subgroup analyses based on age (< 65 vs. ≥ 65 yr), mechanical ventilation status, and patients who survived ICU discharge. We included 497,185 patients; 97,317 had frailty (19.6%). AHRF was more common in patients with frailty compared with those without frailty (58.3% vs. 49.0%). Overall, 7.4% of patients died in hospital (36,791/497,185); a higher proportion were frail (16.4% vs. 5.2%). Mortality rates in patients with frailty with AHRF rose alongside worsening AHRF showing increasing absolute differences in in-hospital mortality as AHRF severity increased. Additionally, within each CFS category, increasing CFS scores also correlated with higher absolute differences in mortality. After adjusting for confounders, there was a nonlinear relationship between frailty, Pa o2 /F io2 , and in-hospital mortality, with a clear separation between each of the CFS categories.
CONCLUSIONS: This multicenter, retrospective study that investigated the association between frailty, AHRF, and in-hospital mortality found that AHRF was highly prevalent in patients with frailty. Increasing frailty was associated with higher in-hospital mortality in AHRF and its increasing severity, with a nonlinear relationship.
参考来源
- Subramaniam A, Ling RR, Burrell A, et al. The Association Between Frailty, Pa o2 /F io2 Ratio, and Hospital Mortality: A Retrospective Registry-Based Cohort Study. Crit Care Med. 2025. PMID: 41123403. doi:10.1097/CCM.0000000000006917
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。